Lemaitre Vasculr Stock Price, News & Analysis

LeMaitre Vascular, Inc. (LMAT) will release its fourth quarter 2021 financial results on February 24, 2022, after market close. A conference call is scheduled for 5:00 PM ET that day to discuss the results and company outlook. The company provides devices and services for peripheral vascular disease, affecting over 200 million people globally. Investors can access the live call by dialing 800-773-2954 or through a webcast on the company's investor relations website.

LeMaitre Vascular announced that CFO JJ Pellegrino will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:30 AM ET. The company specializes in devices and services for treating peripheral vascular disease, impacting over 200 million people globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. More information is available at www.lemaitre.com.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that CFO JJ Pellegrino will present at the 24th Annual Needham Virtual Growth Conference on January 14, 2022, at 3:30 PM. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million people globally. LeMaitre develops a range of disposable and implantable vascular devices aimed at meeting the needs of vascular surgeons. Additional details are available on their website at www.lemaitre.com.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) has announced participation in three upcoming virtual investor conferences:

• Stifel 2021 Virtual Healthcare Conference – November 15, 2021, 8:40 AM ET (David Roberts, President)
• Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum – November 18, 2021 (JJ Pellegrino, CFO)
• Piper Sandler 33rd Virtual Annual Healthcare Conference – November 29 – December 2, 2021 (Pre-recorded presentation by David Roberts)

LeMaitre specializes in medical devices for peripheral vascular disease, serving over 200 million affected patients globally.

LeMaitre (Nasdaq:LMAT) reported Q3 2021 sales of $38.4 million, a 5% increase year-over-year, with a gross margin of 64.8%, up 250 basis points. Operating income dropped 9% to $9.1 million, and net income fell 13% to $6.5 million. Earnings per diluted share were $0.30, down 19%. The company announced a quarterly dividend of $0.11 per share. Guidance for Q4 2021 expects sales between $39.0 million and $41.0 million, with a gross margin of 66.3%. CEO George LeMaitre noted challenges from the Delta variant affecting elective surgeries.

LeMaitre Vascular, Inc. (LMAT) will announce its Q3 2021 financial results on October 28, 2021, following the market's close. A conference call is scheduled for 5:00 PM ET that same day to discuss the results and company outlook. The call can be accessed by dialing 844-239-5284 (international: +1-512-961-6497) and is available via a webcast at www.lemaitre.com/investor. LeMaitre provides vascular devices for treating peripheral vascular disease, serving a global market of over 200 million individuals.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in four virtual investor conferences throughout September 2021. Key events include the Barrington Research 14th Annual Virtual Fall Investment Conference and Morgan Stanley's 19th Annual Global Healthcare Conference, both on September 9. Additionally, LeMaitre will participate in Lake Street's 5th Annual Best Ideas Growth Conference on September 14 and the 2021 Cantor Virtual Global Healthcare Conference on September 27, where David Roberts, President, will present at 8:00 AM ET.

LeMaitre specializes in devices and services for peripheral vascular disease, impacting over 200 million globally.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two investor conferences in August 2021. CFO JJ Pellegrino will present at the Canaccord Genuity 41^st Annual Growth Conference on August 12 at 9:00 AM EDT and will also attend the Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16. LeMaitre specializes in devices and services for treating peripheral vascular disease, which impacts over 200 million people globally.

LeMaitre (Nasdaq:LMAT) reported Q2 2021 results with sales of $40.7 million, a 64% increase year-over-year. Operating income rose by 128% to $11.1 million, yielding an operating margin of 27%. Net income jumped 137% to $8.3 million, with earnings per diluted share at $0.40, a 131% increase. Despite a gross margin decline to 65.8%, driven by product mix and manufacturing inefficiencies, the company completed a $54.5 million follow-on stock offering. Q3 2021 guidance suggests sales between $38.3 million and $40.3 million.